Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Jaksa

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Pricing Additional Benefit in GermanyK Daniel, A Jaksa, Y S Ho
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Is G-Ba Strategically Discounting The Benefit Assessment of Relatively High Cost Drugs?A Jaksa, K Daniel, R Bergemann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Negative Reimbursement Consequences From Trial Design ChoicesA Jaksa, L Westbrook, K Daniel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Nice Restrictiveness Compared To the Market AuthorizationA Jaksa, L Westbrook, E Rubinstein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Nice Restrictiveness Compared to the Market Authorization In Oncology And Non-Oncology ReviewsA Jaksa, L Westbrook, E Rubinstein, et al.
Sleep Medicine|August 23, 2012
Systematic evaluation of Axis-I DSM diagnoses in delayed sleep phase disorder and evening-type circadian preferenceKathryn J Reid, Ashley A Jaksa, Julie B Eisengart, et al.
International Journal of Technology Assessment in Health Care|June 17, 2025
Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision makingAshley A Jaksa, Alina N Pavel, Matti Aapro, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Pricing Additional Benefit in GermanyK Daniel, A Jaksa, Y S Ho
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Is G-Ba Strategically Discounting The Benefit Assessment of Relatively High Cost Drugs?A Jaksa, K Daniel, R Bergemann, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Negative Reimbursement Consequences From Trial Design ChoicesA Jaksa, L Westbrook, K Daniel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Nice Restrictiveness Compared To the Market AuthorizationA Jaksa, L Westbrook, E Rubinstein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Nice Restrictiveness Compared to the Market Authorization In Oncology And Non-Oncology ReviewsA Jaksa, L Westbrook, E Rubinstein, et al.
Sleep Medicine|August 23, 2012
Systematic evaluation of Axis-I DSM diagnoses in delayed sleep phase disorder and evening-type circadian preferenceKathryn J Reid, Ashley A Jaksa, Julie B Eisengart, et al.
International Journal of Technology Assessment in Health Care|June 17, 2025
Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision makingAshley A Jaksa, Alina N Pavel, Matti Aapro, et al.
Pageof 1